BBIO - BridgeBio Pharma, Inc.

65.36
-0.810   -1.239%

Share volume: 3,243,799
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$66.17
-0.81
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 15%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.21%
1 Month
-9.59%
3 Months
-11.96%
6 Months
20.39%
1 Year
107.03%
2 Year
117.87%
Key data
Stock price
$65.36
P/E Ratio 
0.00
DAY RANGE
$63.62 - $66.06
EPS 
-$3.78
52 WEEK RANGE
$28.32 - $84.94
52 WEEK CHANGE
$108.15
MARKET CAP 
14.740 B
YIELD 
N/A
SHARES OUTSTANDING 
193.863 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
1.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,836,827
AVERAGE 30 VOLUME 
$3,622,554
Company detail
CEO: Neil Kumar
Region: US
Website: bridgebio.com
Employees: 400
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.

Recent news